Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
135.4 USD | -0.95% | -2.86% | +2.77% |
May. 31 | Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing | MT |
May. 28 | Neurocrine Biosciences Says CEO Kevin Gorman Retiring | MT |
Financials (USD)
Sales 2024 * | 2.22B | Sales 2025 * | 2.55B | Capitalization | 13.63B |
---|---|---|---|---|---|
Net income 2024 * | 426M | Net income 2025 * | 667M | EV / Sales 2024 * | 5.24 x |
Net cash position 2024 * | 2B | Net cash position 2025 * | 2.81B | EV / Sales 2025 * | 4.24 x |
P/E ratio 2024 * |
33.4
x | P/E ratio 2025 * |
21.4
x | Employees | 1,448 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.2% |
Latest transcript on Neurocrine Biosciences, Inc.
1 day | -0.95% | ||
1 week | -2.86% | ||
1 month | -3.16% | ||
3 months | +3.13% | ||
6 months | +15.62% | ||
Current year | +2.77% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Director of Finance/CFO | 44 | 17-10-31 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-11-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 99-03-31 |
George Morrow
BRD | Director/Board Member | 72 | 15-09-30 |
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
13.65% | 254 M€ | +13.69% | - | |
3.81% | 1 M€ | -.--% | - | |
1.85% | 8 M€ | -.--% | ||
1.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 135.4 | -0.91% | 1,537,370 |
24-05-30 | 136.7 | +1.52% | 761,760 |
24-05-29 | 134.6 | -4.17% | 1,475,886 |
24-05-28 | 140.5 | +0.77% | 569,364 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.77% | 13.63B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.73% | 21.96B | |
-8.24% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+34.58% | 12.27B | |
+77.64% | 8.87B | |
+7.26% | 7.75B |
- Stock Market
- Equities
- NBIX Stock